KR20250103803A - 키나아제 억제제의 결정질 형태 및 염 형태 - Google Patents

키나아제 억제제의 결정질 형태 및 염 형태 Download PDF

Info

Publication number
KR20250103803A
KR20250103803A KR1020257021669A KR20257021669A KR20250103803A KR 20250103803 A KR20250103803 A KR 20250103803A KR 1020257021669 A KR1020257021669 A KR 1020257021669A KR 20257021669 A KR20257021669 A KR 20257021669A KR 20250103803 A KR20250103803 A KR 20250103803A
Authority
KR
South Korea
Prior art keywords
compound
peaks
cell
xrpd pattern
cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020257021669A
Other languages
English (en)
Korean (ko)
Inventor
프레넬 데모린
칼리드 샤
사가 샤키아
페터 옹
커트니 에스. 존슨
멜라니 자넬 베빌
스테판 디 패런트
Original Assignee
엑셀리시스, 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엑셀리시스, 인코포레이티드 filed Critical 엑셀리시스, 인코포레이티드
Publication of KR20250103803A publication Critical patent/KR20250103803A/ko
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020257021669A 2018-12-13 2019-12-12 키나아제 억제제의 결정질 형태 및 염 형태 Pending KR20250103803A (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201862779430P 2018-12-13 2018-12-13
US62/779,430 2018-12-13
US201962856469P 2019-06-03 2019-06-03
US62/856,469 2019-06-03
PCT/US2019/065972 WO2020123800A1 (en) 2018-12-13 2019-12-12 Crystalline forms and salt forms of a kinase inhibitor
KR1020217021734A KR102828472B1 (ko) 2018-12-13 2019-12-12 키나아제 억제제의 결정질 형태 및 염 형태

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020217021734A Division KR102828472B1 (ko) 2018-12-13 2019-12-12 키나아제 억제제의 결정질 형태 및 염 형태

Publications (1)

Publication Number Publication Date
KR20250103803A true KR20250103803A (ko) 2025-07-07

Family

ID=69160358

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020257021669A Pending KR20250103803A (ko) 2018-12-13 2019-12-12 키나아제 억제제의 결정질 형태 및 염 형태
KR1020217021734A Active KR102828472B1 (ko) 2018-12-13 2019-12-12 키나아제 억제제의 결정질 형태 및 염 형태

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020217021734A Active KR102828472B1 (ko) 2018-12-13 2019-12-12 키나아제 억제제의 결정질 형태 및 염 형태

Country Status (33)

Country Link
US (2) US12017995B2 (cg-RX-API-DMAC7.html)
EP (2) EP4631505A3 (cg-RX-API-DMAC7.html)
JP (3) JP7509779B2 (cg-RX-API-DMAC7.html)
KR (2) KR20250103803A (cg-RX-API-DMAC7.html)
CN (1) CN113329790A (cg-RX-API-DMAC7.html)
AU (2) AU2019395419B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021011333A2 (cg-RX-API-DMAC7.html)
CA (1) CA3122840A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021001537A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021007613A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210375A (cg-RX-API-DMAC7.html)
DK (1) DK3894012T3 (cg-RX-API-DMAC7.html)
ES (1) ES3052838T3 (cg-RX-API-DMAC7.html)
FI (1) FI3894012T3 (cg-RX-API-DMAC7.html)
GE (1) GEP20247596B (cg-RX-API-DMAC7.html)
HR (1) HRP20251122T1 (cg-RX-API-DMAC7.html)
HU (1) HUE072868T2 (cg-RX-API-DMAC7.html)
IL (2) IL283860B2 (cg-RX-API-DMAC7.html)
LT (1) LT3894012T (cg-RX-API-DMAC7.html)
MA (1) MA54458B1 (cg-RX-API-DMAC7.html)
MD (1) MD3894012T2 (cg-RX-API-DMAC7.html)
MX (1) MX2021006951A (cg-RX-API-DMAC7.html)
PE (1) PE20211757A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021551356A1 (cg-RX-API-DMAC7.html)
PL (1) PL3894012T4 (cg-RX-API-DMAC7.html)
PT (1) PT3894012T (cg-RX-API-DMAC7.html)
RS (1) RS67216B1 (cg-RX-API-DMAC7.html)
SG (1) SG11202105949RA (cg-RX-API-DMAC7.html)
SI (1) SI3894012T1 (cg-RX-API-DMAC7.html)
SM (1) SMT202500346T1 (cg-RX-API-DMAC7.html)
TW (2) TWI913821B (cg-RX-API-DMAC7.html)
WO (1) WO2020123800A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202103844B (cg-RX-API-DMAC7.html)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20251184T1 (hr) * 2018-01-26 2025-12-05 Exelixis, Inc. Spojevi za liječenje poremećaja ovisnih o kinazi
PL3894012T4 (pl) * 2018-12-13 2026-01-05 Exelixis, Inc. Postacie krystaliczne i postacie soli inhibitora kinazy
KR102826380B1 (ko) * 2019-06-03 2025-06-26 엑셀리시스, 인코포레이티드 카이네이스 저해제의 결정질 염 형태
FI4143169T3 (fi) * 2020-04-30 2026-06-08 Exelixis Inc Kinaasi-inhibiittorin valmistusmenetelmät
PH12023550160A1 (en) 2020-07-31 2023-09-18 Exelixis Inc Combinations for the Treatment of Cancer
IL302485A (en) * 2020-11-05 2023-06-01 Exelixis Inc Kinase inhibitor pharmaceutical preparations
CN112650176B (zh) * 2020-12-22 2022-08-30 天能化工有限公司 一种盐酸解析开停车工序的dcs控制方法
AR127561A1 (es) * 2021-11-03 2024-02-07 Exelixis Inc Compuestos para el tratamiento de trastornos dependientes de cinasas
AU2022420610A1 (en) 2021-12-22 2024-06-27 Exelixis, Inc. Crystalline forms and salt forms of a kinase inhibitor
CN116751161A (zh) * 2023-06-28 2023-09-15 中国人民解放军军事科学院军事医学研究院 喹啉类化合物及其制备方法、药物组合物及医药用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2210607B1 (en) 2003-09-26 2011-08-17 Exelixis Inc. N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide for the treatment of cancer
WO2006113546A2 (en) 2005-04-15 2006-10-26 Neogenix Oncology, Inc. Recombinant monoclonal antibodies and corresponding antigens for colon and pancreatic cancers
JP4667537B2 (ja) 2008-04-10 2011-04-13 大鵬薬品工業株式会社 アシルチオウレア化合物又はその塩、及びその用途
AU2009303602B2 (en) 2008-10-14 2012-06-14 Sunshine Lake Pharma Co., Ltd. Compounds and methods of use
TW201920110A (zh) 2009-01-16 2019-06-01 美商艾克塞里克斯公司 包含n-(4-{[6,7-雙(甲氧基)喹啉-4-基]氧基}苯基)-n'-(4-氟苯基)環丙烷-1,1-二甲醯胺之蘋果酸鹽之醫藥組合物及其用途
CN102408411B (zh) 2011-09-19 2014-10-22 北京康辰药业股份有限公司 一种含喹啉基的羟肟酸类化合物及其制备方法、以及含有该化合物的药物组合物及其应用
BR112015007672A2 (pt) 2012-10-04 2017-08-08 Dana Farber Cancer Inst Inc anticorpos anti-pd-l1 monoclonais humanos e métodos de uso
RS61400B1 (sr) 2013-05-02 2021-02-26 Anaptysbio Inc Antitela usmerena protiv programirane smrti-1 (pd-1)
EA032757B1 (ru) 2014-02-14 2019-07-31 Экселиксис, Инк. Кристаллические твердые формы n-{4-[(6,7-диметоксихинолин-4-ил)окси]фенил}-n'-(4-фторфенил)циклопропан-1,1-дикарбоксамида, способы получения и способы применения
CN104817497B (zh) 2015-03-20 2017-03-08 南京众睿缘生物科技有限公司 一种炔代喹啉衍生物及其制备方法和用途
MX2019012505A (es) 2017-05-26 2019-12-19 Exelixis Inc Formas solidas cristalinas de sales de ciclopropano-1,1-dicarboxam ida de n-{4-[(6,7-dimetoxiquinolin-4-il)oxi]fenil}-n'-(4-fluorofen il), procesos para realizarlas y metodos de uso.
HRP20251184T1 (hr) 2018-01-26 2025-12-05 Exelixis, Inc. Spojevi za liječenje poremećaja ovisnih o kinazi
PL3894012T4 (pl) * 2018-12-13 2026-01-05 Exelixis, Inc. Postacie krystaliczne i postacie soli inhibitora kinazy
KR102826380B1 (ko) * 2019-06-03 2025-06-26 엑셀리시스, 인코포레이티드 카이네이스 저해제의 결정질 염 형태

Also Published As

Publication number Publication date
JP2024038167A (ja) 2024-03-19
IL283860B2 (en) 2025-10-01
IL320433A (en) 2025-06-01
US20230029213A1 (en) 2023-01-26
HRP20251122T1 (hr) 2025-11-21
LT3894012T (lt) 2025-10-10
MX2021006951A (es) 2021-07-15
IL283860A (en) 2021-07-29
EP4631505A2 (en) 2025-10-15
AU2019395419A1 (en) 2021-07-01
CN113329790A (zh) 2021-08-31
JP7509779B2 (ja) 2024-07-02
GEP20247596B (en) 2024-02-26
PL3894012T3 (pl) 2026-01-05
JP2026031599A (ja) 2026-02-24
EP4631505A3 (en) 2025-12-10
ZA202103844B (en) 2024-11-27
JP7783870B2 (ja) 2025-12-10
TW202039440A (zh) 2020-11-01
WO2020123800A1 (en) 2020-06-18
JP2022512399A (ja) 2022-02-03
KR20210102381A (ko) 2021-08-19
PL3894012T4 (pl) 2026-01-05
HUE072868T2 (hu) 2025-12-28
PH12021551356A1 (en) 2021-12-06
CO2021007613A2 (es) 2021-06-21
MA54458B1 (fr) 2025-09-30
RS67216B1 (sr) 2025-10-31
CL2021001537A1 (es) 2022-02-04
ES3052838T3 (en) 2026-01-15
CA3122840A1 (en) 2020-06-18
SI3894012T1 (sl) 2025-10-30
AU2025234277A1 (en) 2025-10-16
MA54458A (fr) 2021-10-20
SG11202105949RA (en) 2021-07-29
TWI913821B (zh) 2026-02-01
KR102828472B1 (ko) 2025-07-03
DK3894012T3 (da) 2025-09-15
PE20211757A1 (es) 2021-09-07
TWI852963B (zh) 2024-08-21
AU2019395419B2 (en) 2025-06-26
BR112021011333A2 (pt) 2021-08-31
MD3894012T2 (ro) 2025-11-30
US12679809B2 (en) 2026-07-14
EP3894012B1 (en) 2025-06-18
EP3894012A1 (en) 2021-10-20
TW202519513A (zh) 2025-05-16
SMT202500346T1 (it) 2025-11-10
CR20210375A (es) 2021-08-18
PT3894012T (pt) 2025-09-25
FI3894012T3 (fi) 2025-09-18
US12017995B2 (en) 2024-06-25
US20240300897A1 (en) 2024-09-12
IL283860B1 (en) 2025-06-01

Similar Documents

Publication Publication Date Title
KR102828472B1 (ko) 키나아제 억제제의 결정질 형태 및 염 형태
KR102826380B1 (ko) 카이네이스 저해제의 결정질 염 형태
US20250368606A1 (en) Crystalline forms and salt forms of a kinase inhibitor
HK40061293A (en) Crystalline forms and salt forms of a kinase inhibitor
HK40061293B (en) Crystalline forms and salt forms of a kinase inhibitor
EA048718B1 (ru) Кристаллические солевые формы ингибитора киназы
HK40067664A (en) Crystalline salt forms of a kinase inhibitor
BR122025022768A2 (pt) Formas cristalinas, sais de ácido clorídrico e ácido fosfórico cristalinos, composição farmacêutica e usos relacionados
EA044424B1 (ru) Кристаллические формы и солевые формы ингибитора киназы

Legal Events

Date Code Title Description
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

Q12 Application published

Free format text: ST27 STATUS EVENT CODE: A-1-1-Q10-Q12-NAP-PG1501 (AS PROVIDED BY THE NATIONAL OFFICE)